Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis

Journal of Heart and Lung Transplantation

Volumn 33, Issue 2, 2014, Pages 149-156

  Gray Gilstrap, Lauren ^a   Niehaus, Emily ^a   Malhotra, Rajeev ^a   Ton, Van Khue ^b   Watts, James ^c   Seldin, David C ^d   Madsen, Joren C ^a   Semigran, Marc J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c BROOKE ARMY MEDICAL CENTER   (United States)

^d BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

autologous stem cell transplant; body mass index; light chain cardiac amyloidosis; orthotopic heart transplantation; survival

Indexed keywords

AUTOLOGOUS STEM CELL TRANSPLANT; BODY MASS INDEX; LIGHT-CHAIN CARDIAC AMYLOIDOSIS; ORTHOTOPIC HEART TRANSPLANTATION; SURVIVAL;

AMYLOIDOSIS; BODY MASS INDEX; CARDIOMYOPATHIES; FEMALE; HEART DISEASES; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TIME FACTORS; WAITING LISTS;

EID: 84895061645     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2013.09.004     Document Type: Article

References (33)

1. S.W. Dubrey, K. Cha, and J. Anderson et al. The clinical features of immunoglobulin light-chain (al) amyloidosis with heart involvement QJM 91 1998 141 157
2. R.A. Kyle, M.A. Gertz, and P.R. Greipp et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine N Engl J Med 336 1997 1202 1207
3. G. Merlini, D.C. Seldin, and M.A. Gertz Amyloidosis: pathogenesis and new therapeutic options J Clin Oncol 29 2011 1924 1933
4. E. Kastritis, A.D. Wechalekar, and M.A. Dimopoulos et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis J Clin Oncol 28 2010 1031 1037
5. M. Skinner, V. Sanchorawala, and D.C. Seldin et al. High-dose melphalan and autologous stem-cell transplantation in patients with al amyloidosis: an 8-year study Ann Intern Med 140 2004 85 93
6. E.L. Comenzo, and M.A. Gertz Autologous stem cell transplantation for primary systemic amyloidosis Blood 99 2002 4276 4282
7. A.D. Wechalecher, S.O. Schonland, and E. Kastritis et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis Blood 121 2013 3420 3427
8. Hosenpud JD, DeMarco T, Frazier OH, et al. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. Circulation 1991;84:III338-43
9. S.W. Dubrey, M.M. Burke, P.N. Hawkins, and N.R. Banner Cardiac transplantation for amyloid heart disease: the United Kingdom experience J Heart Lung Transplant 23 2004 1142 1153
10. S.O. Schonland, H. Lokhorst, and A. Buzyn et al. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation Blood 107 2006 2578 2584
11. M.S. Maurer, A. Raina, and C. Hesdorffer et al. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure Transplantation 83 2007 539 545
12. M.Q. Lacy, A. Dispenzieri, and S.R. Hayman et al. Autologous stem cell transplant after heart transplant for light chain (al) amyloid cardiomyopathy J Heart Lung Transplant 27 2008 823 829
13. B.R. Dey, S.S. Chung, and T.R. Spitzer et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure Transplantation 90 2010 905 911
14. L.A. Stevens, J. Coresh, T. Greene, and A.S. Levey Assessing kidney function - measured and estimated glomerular filtration rate N Engl J Med 354 2006 2473 2483
15. A. Dispenzieri, M.Q. Lacy, and S.R. Zeldenrust et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis Blood 109 2007 465 470
16. V. Sanchorawala, D.G. Wright, and M. Rosenzweig et al. Lenalidomide and dexamethasone in the treatment of al amyloidosis: results of a phase 2 trial Blood 109 2007 492 496
17. P. Moreau, A. Jaccard, and L. Benboubker et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed al amyloidosis: a multicenter phase 1/2 dose-escalation study Blood 116 2010 4777 4782
18. E. Kastritis, A. Anagnostopoulos, and M. Roussou et al. Treatment of light chain (al) amyloidosis with the combination of bortezomib and dexamethasone Haematologica 92 2007 1351 1358
19. A.D. Wechalekar, H.J. Lachmann, M. Offer, P.N. Hawkins, and J.D. Gillmore Efficacy of bortezomib in systemic al amyloidosis with relapsed/refractory clonal disease Haematologica 93 2008 295 298
20. R. Sitia, G. Palladini, and G. Merlini Bortezomib in the treatment of al amyloidosis: targeted therapy? Haematologica 92 2007 1302 1307
21. R.H. Falk Cardiac amyloidosis a treatable disease, often overlooked Circulation 124 2011 1079 1085
22. B.C. Varr, M. Liedtke, S. Arai, R.A. Lafayette, S.L. Schrier, and R.M. Witteles Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies J Heart Lung Transplant 31 2012 325 331
23. S. Parikh, and J.A. de Lemos Current therapeutic strategies in cardiac amyloidosis Curr Treat Options Cardiovasc Med 7 2005 443 448
24. P. Panduranga, and M. Mukhaini Catastrophic cardiac amyloidosis Cardiol Res Pract 2011 2010 479314
25. M. Toma, and R.C. Starling Inotropic therapy for end-stage heart failure patients Curr Treat Options Cardiovasc Med 12 2010 409-409
26. S.W. Dubrey, M.M. Burke, A. Khaghani, P.N. Hawkins, M.H. Yacoub, and N.R. Banner Long term results of heart transplantation in patients with amyloid heart disease Heart 85 2001 202 207
27. H. Kita, N. Kokubu, and T. Yoshioka et al. A case of cardiac amyloidosis with incurable heart failure J Kushiro City Gen Hosp 13 2001 118 121
28. R.V. Cantwell, R.J. Aviles, and J. Bjornsson et al. Cardiac amyloidosis presenting with elevations of cardiac troponin i and angina pectoris Clin Cardiol 25 2002 33 37
29. G.J. Fitzmaurice, V. Wishart, and A.N. Graham An unexpected mortality following cardiac surgery: a post-mortem diagnosis of cardiac amyloidosis Gen Thorac Cardiovasc Surg 61 2013 417 421
30. M.P. Siegenthaler, J. Martin, A. van de Loo, T. Doenst, W. Bothe, and F. Beyersdorf Implantation of the permanent jarvik-2000 left ventricular assist device: a single-center experience J Am College of Cardiol 39 2002 1764 1772
31. G.D. Fotopoulos, M.J. Mason, S. Walker, N.S. Jepson, D.J. Patel, and A.G. Mitchell et al. Stabilisation of medically refractory ventricular arrhythmia by intra-aortic balloon counterpulsation Heart 82 1999 96 100
32. Y. Onoue, Y. Izumiya, S. Takashio, T. Ono, K. Morihisa, and K. Tsujita et al. Multidisciplinary mechanical supports improve outcome in a shock patient with cardiac amyloidosis: a case report Intern Med 51 2012 1215 1219
33. J. Estep, A. Bhimaraj, A. Cordero-Reyes, B. Bruckner, M. Loebe, and G. Torre-Amione Heart transplantation and end-stage cardiac amyloidosis: a review and approach to evaluation and management Methodist Debakey Cardiovasc J 8 2012 8 16